Bor-Shiuan Chuang, MD
Psychiatry · Copiague, NYNPI 1003997255
Payments from drug & device makers
Across 337 payments — averaging $46.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$875
- plus $2K from 8 others
What the payments were for
- Food & beverage$14,99496%
- Education$5494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 77 | $3,690 |
| Teva Pharmaceuticals USA, Inc. | 72 | $3,208 |
| Otsuka America Pharmaceutical, Inc. | 28 | $2,105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $2,029 |
| Neurocrine Biosciences, Inc. | 25 | $1,201 |
| E.r. Squibb & Sons, L.L.C. | 14 | $875 |
| Johnson & Johnson | 18 | $636 |
| Axsome Therapeutics, Inc. | 5 | $508 |
| Sunovion Pharmaceuticals Inc. | 18 | $477 |
| Lundbeck LLC | 17 | $360 |
| AbbVie | 2 | $247 |
| Indivior Inc. | 7 | $134 |
| Luye Pharma (USA) Ltd. | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$6,132
- LYBALVI$3,756
- ARISTADA INITIO$1,533
- ABILIFY MAINTENA$1,337
- CAPLYTA$1,208
- INGREZZA$865
- UZEDY$725
- AUSTEDO$669
- COBENFY$592
- REXULTI$497
- Austedo XR$494
- ABILIFY ASIMTUFII$487
- Auvelity$483
- INVEGA SUSTENNA$250
- VRAYLAR$247
- LATUDA$242
- INVEGA TRINZA$125
How this compares
$15,543 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 31 | $304,438 |
| Invega SustennaPaliperidone Palmitate | 102 | $279,804 |
| IngrezzaValbenazine Tosylate | 20 | $172,896 |
| Abilify MaintenaAripiprazole | 38 | $111,410 |
| Abilify AsimtufiiAripiprazole | 12 | $72,874 |
| CaplytaLumateperone Tosylate | 17 | $27,693 |
| Lurasidone Hcl | 63 | $24,809 |
| VraylarCariprazine Hcl | 14 | $20,952 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,550 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $16,467 |
| Aripiprazole | 208 | $13,508 |
| TrintellixVortioxetine Hydrobromide | 24 | $12,113 |
| Ziprasidone Hcl | 71 | $4,251 |
| Quetiapine Fumarate | 169 | $4,002 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 63 | $2,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $3,208 | $304,43831 claims |
| Johnson & JohnsonInvega Sustenna | $636 | $279,804102 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii | $2,105 | $184,28450 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,201 | $172,89620 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,029 | $27,69317 claims |
| AbbVieVraylar | $247 | $20,95214 claims |
| Alkermes, Inc.Lybalvi | $3,690 | $19,55012 claims |
| Axsome Therapeutics, Inc.Auvelity | $508 | $16,46713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Copiague
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.